Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Feb 1;30(3):474-476.
doi: 10.1158/1078-0432.CCR-23-2991.

Pancreatic Cancer's PD1-Roadblock: When T-Cell Reinvigoration Is Not Enough

Varintra E Lander  1   2 , David G DeNardo  1   2   3
Affiliations
Comment

Pancreatic Cancer's PD1-Roadblock: When T-Cell Reinvigoration Is Not Enough

Varintra E Lander et al. Clin Cancer Res. .

Abstract

PD1-blockade combinations in pancreatic ductal adenocarcinoma have been poorly effective, and the underlying reasons for this are unknown. A recent study revealed that chemoradiation plus PD1-blockade reinvigorates tumor-specific T cells; however, this T-cell activation is accompanied with exaggerated NFκB signaling, which may limit productive tumor-controlling immunity. See related article by Ali et al., p. 542.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The authors have no conflicts of interest to declare.

Figures

Figure 1:
Figure 1:
Schematic representation of the trial design, which involved adding PD1-blockade to standard of care radiation therapies. Analysis of T cells from blood and tissue samples showed that the addition of PD1-blockade leads to both productive T cell changes (green arrow) as well as non-productive outcomes (red arrow). The key determinants driving a productive vs. non-productive T cell response to PD1-blockade are unknown, but likely critical to many immunotherapy-resitant cancers including PDAC.
See this image and copyright information in PMC

Comment on

References

    1. Ali LR, Lenehan PJ, Cardot-Ruffino V, Dias Costa A, Katz MHG, Bauer TW, et al. PD-1 blockade induces reactivation of non-productive T cell responses characterized by NF-kB signaling in patients with pancreatic cancer. Clin Cancer Res 2023. doi 10.1158/1078-0432.Ccr-23-1444. - DOI - PMC - PubMed
    1. Bear AS, Vonderheide RH, O’Hara MH. Challenges and Opportunities for Pancreatic Cancer Immunotherapy. Cancer Cell 2020;38(6):788–802 doi 10.1016/j.ccell.2020.08.004. - DOI - PMC - PubMed
    1. Xie C, Duffy AG, Brar G, Fioravanti S, Mabry-Hrones D, Walker M, et al. Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 2020;26(10):2318–26 doi 10.1158/1078-0432.Ccr-19-3624. - DOI - PMC - PubMed
    1. Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 2020;38(1):1–10 doi 10.1200/jco.19.02105. - DOI - PMC - PubMed
    1. Falcomatà C, Bärthel S, Schneider G, Rad R, Schmidt-Supprian M, Saur D. Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer. Cancer Discov 2023;13(2):278–97 doi 10.1158/2159-8290.Cd-22-0876. - DOI - PMC - PubMed

Publication types

MeSH terms